Literature DB >> 24744596

Single hepatocellular carcinoma ≤ 3 cm in left lateral segment: liver resection or radiofrequency ablation?

Jong Man Kim1, Tae Wook Kang1, Choon Hyuck David Kwon1, Jae-Won Joh1, Justin Sangwook Ko1, Jae Berm Park1, Hyunchul Rhim1, Joon Hyeok Lee1, Sung Joo Kim1, Seung Woon Paik1.   

Abstract

AIM: To evaluate the long-term results of radiofrequency ablation (RFA) compared to left lateral sectionectomy (LLS) in patients with Child-Pugh class A disease for the treatment of single and small hepatocellular carcinoma (HCC) in the left lateral segments.
METHODS: We retrospectively reviewed the data of 133 patients with single HCC (≤ 3 cm) in their left lateral segments who underwent curative LLS (n = 66) or RFA (n = 67) between 2006 and 2010.
RESULTS: The median follow-up period was 33.5 mo in the LLS group and 29 mo in the RFA group (P = 0.060). Most patients had hepatitis B virus-related HCC. The hospital stay was longer in the LLS group than in the RFA group (8 d vs 2 d, P < 0.001). The 1-, 2-, and 3-year disease-free survival and overall survival rates were 80.0%, 68.2%, and 60.0%, and 95.4%, 92.3%, and 92.3%, respectively, for the LLS group; and 80.8%, 59.9%, and 39.6%, and 98.2%, 92.0%, and 74.4%, respectively, for the RFA group. The disease-free survival curve and overall survival curve were higher in the LLS group than in the RFA group (P = 0.012 and P = 0.013, respectively). Increased PIVKA-II levels and small tumor size were associated with HCC recurrence in multivariate analysis.
CONCLUSION: Liver resection is suitable for single HCC ≤ 3 cm in the left lateral segments.

Entities:  

Keywords:  Left lateral segment; Liver resection; Radiofrequency ablation; Small hepatocellular carcinoma; Survival; Tumor recurrence

Mesh:

Year:  2014        PMID: 24744596      PMCID: PMC3983463          DOI: 10.3748/wjg.v20.i14.4059

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Partial hepatectomy versus radiofrequency ablation for hepatocellular carcinoma: confirming the trial that will never be, and some comments on the indications for liver resection.

Authors:  Pietro E Majno; Gilles Mentha; Vincenzo Mazzaferro
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

2.  Laparoscopic left lateral liver resection should be a standard operation.

Authors:  Ahsan Rao; Ghaus Rao; Irfan Ahmed
Journal:  Surg Endosc       Date:  2010-12-07       Impact factor: 4.584

3.  A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria.

Authors:  Jiwei Huang; Lvnan Yan; Zheyu Cheng; Hong Wu; Liang Du; Jinzhou Wang; Yinglong Xu; Yong Zeng
Journal:  Ann Surg       Date:  2010-12       Impact factor: 12.969

4.  Surveillance for hepatocellular carcinoma in patients with cirrhosis.

Authors:  Ju Dong Yang; W Ray Kim
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-13       Impact factor: 11.382

Review 5.  Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2010-07-08       Impact factor: 2.935

Review 6.  Hepatocellular carcinoma: current management and perspectives for the future.

Authors:  Nuh N Rahbari; Arianeb Mehrabi; Nathan M Mollberg; Sascha A Müller; Moritz Koch; Markus W Büchler; Jürgen Weitz
Journal:  Ann Surg       Date:  2011-03       Impact factor: 12.969

7.  Ultrasonography-guided percutaneous radiofrequency ablation of hepatocellular carcinomas: a feasibility scoring system for planning sonography.

Authors:  Hyunchul Rhim; Dongil Choi; Young-sun Kim; Hyo K Lim; Bong-Keun Choe
Journal:  Eur J Radiol       Date:  2009-05-07       Impact factor: 3.528

Review 8.  Novel advancements in the management of hepatocellular carcinoma in 2008.

Authors:  Josep M Llovet; Jordi Bruix
Journal:  J Hepatol       Date:  2008-02-12       Impact factor: 25.083

9.  Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors.

Authors:  Shuji Sumie; Ryoko Kuromatsu; Koji Okuda; Eiji Ando; Akio Takata; Nobuyoshi Fukushima; Yasutomo Watanabe; Masamichi Kojiro; Michio Sata
Journal:  Ann Surg Oncol       Date:  2008-03-07       Impact factor: 5.344

Review 10.  Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma.

Authors:  Yanming Zhou; Yanfang Zhao; Bin Li; Donghui Xu; Zhengfeng Yin; Feng Xie; Jiamei Yang
Journal:  BMC Gastroenterol       Date:  2010-07-09       Impact factor: 3.067

View more
  9 in total

1.  Experience With Changing Etiology and Nontransplant Curative Treatment Modalities for Hepatocellular Carcinoma in a Real-Life Setting-A Retrospective Descriptive Analysis.

Authors:  Suneel Tohra; Ajay Duseja; Sunil Taneja; Naveen Kalra; Ujjwal Gorsi; Arunanshu Behera; Lileswar Kaman; Divya Dahiya; Srimanta Sahu; Balkrishan Sharma; Virendra Singh; Radha K Dhiman; Yogesh Chawla
Journal:  J Clin Exp Hepatol       Date:  2021-02-11

2.  Shall we take a second thought before applying radiofrequency ablation for resectable HCC ≤2 cm?

Authors:  Mingheng Liao; Jiwei Huang; Hong Wu; Yong Zeng
Journal:  Hepatobiliary Surg Nutr       Date:  2014-06       Impact factor: 7.293

Review 3.  Radiofrequency ablation versus resection for Barcelona clinic liver cancer very early/early stage hepatocellular carcinoma: a systematic review.

Authors:  Zhen-Xin He; Pu Xiang; Jian-Ping Gong; Nan-Sheng Cheng; Wei Zhang
Journal:  Ther Clin Risk Manag       Date:  2016-02-23       Impact factor: 2.423

4.  Clinical outcomes of laparoscopic radiofrequency ablation of single primary or recurrent hepatocellular carcinoma (≤3 cm).

Authors:  Byung Gon Na; Jong Man Kim; Dong Kyu Oh; Kyo-Won Lee; Tae-Wook Kang; Gyu-Seong Choi; Min Woo Lee; Choon Hyuck David Kwon; Hyun Chul Lim; Jae-Won Joh
Journal:  Ann Surg Treat Res       Date:  2017-04-27       Impact factor: 1.859

5.  Radiofrequency Ablation Combined with Transcatheter Arterial Chemoembolization Therapy Versus Surgical Resection for Hepatocellular Carcinoma within the Milan Criteria: A Meta-Analysis.

Authors:  Wei-Dong Wang; Li-Hua Zhang; Jia-Yan Ni; Xiong-Ying Jiang; Dong Chen; Yao-Ting Chen; Hong-Liang Sun; Jiang-Hong Luo; Lin-Feng Xu
Journal:  Korean J Radiol       Date:  2018-06-14       Impact factor: 3.500

6.  A new scoring model predicting macroscopic vascular invasion of early-intermediate hepatocellular carcinoma.

Authors:  Yao Liu; Le Sun; Fangyuan Gao; Xue Yang; Yuxin Li; Qun Zhang; Bingbing Zhu; Shuaishuai Niu; Yunyi Huang; Ying Hu; Ying Feng; Yuyong Jiang; Xianbo Wang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Radiofrequency ablation combined with transcatheter arterial chemoembolization therapy versus surgical resection for Barcelona-Clinic Liver Cancer (BCLC) A hepatocellular carcinoma: a meta-analysis.

Authors:  Weidong Wang; Sinan Hou; Zelong Zhong; JiaYan Ni; Xiongying Jiang; Dong Chen; Yaoting Chen; Jianghong Luo; Hongliang Sun; Linfeng Xu
Journal:  J Interv Med       Date:  2019-04-30

8.  Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis.

Authors:  Hongcui Cao; Lanjuan Li; Guo Tian; Shigui Yang; Jinqiu Yuan; Diane Threapleton; Qiyu Zhao; Fen Chen; Tian'an Jiang
Journal:  BMJ Open       Date:  2018-10-18       Impact factor: 2.692

9.  Preferred Treatment with Curative Intent for Left Lateral Segment Early Hepatocellular Carcinoma under the Era of Minimal Invasive Surgery.

Authors:  Tsung-Han Wu; Yu-Chao Wang; Hao-Chien Hung; Jin-Chiao Lee; Chia-Ying Wu; Chih-Hsien Cheng; Chen-Fang Lee; Ting-Jung Wu; Hong-Shiue Chou; Kun-Ming Chan; Wei-Chen Lee
Journal:  J Pers Med       Date:  2022-01-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.